Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2022-02-01 Major Shareholding Noti…
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or updates by a company. The text includes a detailed description of a webcast fireside chat providing a data and regulatory update related to clinical trial results and FDA actions. It does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It also does not fit categories like Earnings Release (ER) or Management Reports (MDA) because it focuses on regulatory and clinical updates rather than financial results. The document is not a certification or attestation, so it is not Regulatory Filings (RNS) by the certification rule. The content is an update on regulatory and clinical trial status, which is typically reported in an 8-K filing. Therefore, the best classification is Regulatory Filings (RNS), as 8-K filings are general regulatory announcements that do not fit other specific categories.
2022-01-27 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-01-08 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-01-08 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a loan and security agreement, detailing changes in loan amounts, terms, interest rates, and warrants issued. It does not contain comprehensive financial statements or detailed financial performance data. Instead, it is an update on financing activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not merely an announcement of a report but a substantive filing about financing.
2022-01-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 30, 2021. It announces a press release about the FDA's plan to host an advisory committee meeting related to a drug application review. It also mentions a conference call to discuss regulatory updates. The document does not contain financial statements or detailed financial data but is an announcement of an event and related press release. The length is 3473 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this is a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like earnings release or management report.
2021-11-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.